Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Madruga JV, et al. Among authors: ruxrungtham k. Lancet. 2007 Jul 7;370(9581):49-58. doi: 10.1016/S0140-6736(07)61049-6. Lancet. 2007. PMID: 17617272 Clinical Trial.
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
Kroon ED, Ungsedhapand C, Ruxrungtham K, Chuenyam M, Ubolyam S, Newell ME, van Leeuwen R, Kunanusont C, Buranapraditkul S, Sirivichayakul S, Lange JM, Cooper DA, Phanuphak P. Kroon ED, et al. Among authors: ruxrungtham k. AIDS. 2000 Jul 7;14(10):1349-56. doi: 10.1097/00002030-200007070-00007. AIDS. 2000. PMID: 10930149 Clinical Trial.
A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand.
Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, Buranapraditkun S, Techasathit W, Li Y, Emery S, Davey RT, Fosdick L, Kunanusont C, Lane HC, Phanuphak P; Vanguard Study Group. Ruxrungtham K, et al. AIDS. 2000 Nov 10;14(16):2509-13. doi: 10.1097/00002030-200011100-00013. AIDS. 2000. PMID: 11101062 Clinical Trial.
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.
Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, Bernasconi E, Cavassini M, Ebnöther C, Fagard C, Genné D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza P, Yerly S; Swiss HIV Cohort Study. Ananworanich J, et al. Among authors: ruxrungtham k. AIDS. 2003 Oct 17;17(15):F33-7. doi: 10.1097/00002030-200310170-00001. AIDS. 2003. PMID: 14523294 Clinical Trial.
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team. van Leth F, et al. Among authors: ruxrungtham k. Lancet. 2004 Apr 17;363(9417):1253-63. doi: 10.1016/S0140-6736(04)15997-7. Lancet. 2004. PMID: 15094269 Clinical Trial.
HIV/AIDS in Asia.
Ruxrungtham K, Brown T, Phanuphak P. Ruxrungtham K, et al. Lancet. 2004 Jul 3-9;364(9428):69-82. doi: 10.1016/S0140-6736(04)16593-8. Lancet. 2004. PMID: 15234860 Review.
Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, Prasithsirikul W, Sankote J, Mahanontharit A, Ruxrungtham K. Manosuthi W, et al. Among authors: ruxrungtham k. AIDS. 2005 Sep 23;19(14):1481-6. doi: 10.1097/01.aids.0000183630.27665.30. AIDS. 2005. PMID: 16135901 Clinical Trial.
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Nüesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B; Staccato Study Group; Swiss HIV Cohort Study. Ananworanich J, et al. Among authors: ruxrungtham k. Lancet. 2006 Aug 5;368(9534):459-65. doi: 10.1016/S0140-6736(06)69153-8. Lancet. 2006. PMID: 16890832 Clinical Trial.
389 results